GTX 201
Alternative Names: GTX-201Latest Information Update: 29 Oct 2024
At a glance
- Originator Grace Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
- Discontinued Trigeminal neuralgia
Most Recent Events
- 25 Oct 2024 Acasti Pharma is now called Grace Therapeutics
- 19 Oct 2024 Acasti Pharma Pipeline, October 2024: No updates; one specific indication dev line was already discontinued as not present on the current pipeline and unknown indication dev line is in active state for preclinical development
- 29 Aug 2024 Discontinued - Phase-I for Trigeminal neuralgia (unspecified route) (Acasti Pharma pipeline, August 2024)